Gastrointestinal | Page 19 of 23

Asthma :: PULMICORT RESPULES, budesonide inhalation suspension controls Asthma

Children treated with PULMICORT RESPULES? (budesonide inhalation suspension) either once or twice daily experienced a significantly greater increase in the percentage of asthma-control days compared to those receiving placebo. These results are being presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI), held in Philadelphia on November 9-15. Asthma-control days were defined as days when children were free of symptoms and did not use rescue medications during the day and night. Control of asthma symptoms during the day and night and reduction of the need for rescue medication is an important goal of asthma therapy in keeping with current National Asthma Education and Prevention Program (NAEPP) guidelines.

Childhood Acid Reflux Disease Poses Challenges for Many Families, National Survey Reveals

Almost everyone suffers from occasional heartburn, even kids. However, if symptoms are persistent and occur two or more days a week, it could signify a condition known as acid reflux disease, commonly known as GERD, which affects roughly two to eight percent of children in the United States. A recent online survey conducted by StrategyOne found that GERD can have a significant impact on kids? lifestyles, and nearly four in ten (38%) parents wished they had more resources about GERD in children.

AstraZeneca Announces New Program That Offers Significant And Convenient Savings For Medicare Part D Enrollees

AstraZeneca announced a new program that provides significant savings to Medicare Part D beneficiaries who may have difficulty affording their medicines. Beginning Nov. 15, people who qualify and enroll will be able to go to their participating local pharmacy and immediately receive savings on AstraZeneca products, including NEXIUM? (esomeprazole), CRESTOR? (rosuvastatin), SEROQUEL? (quetiapine fumarate), TOPROL XL? (metoprolol succinate) and ARIMIDEX? (anastrozole). This is a unique offering in comparison to other patient assistance programs because it gives people convenient savings on their medicines at the pharmacy counter.

Osteoarthritis :: Prexige in the European Union as a new treatment option for osteoarthritic pain

Novartis announced today that Prexige? (lumiracoxib), an oral selective COX-2 inhibitor anti-inflammatory drug, has been cleared for approval in the European Union as a new treatment option for patients suffering from osteoarthritis. This is the most common form of arthritis and a leading cause of chronic pain[2].

Health :: FDA issues approvable letter for Entereg for POI

GlaxoSmithKline (NYSE: GSK) and Adolor Corporation (Nasdaq: ADLR) announced that the Food and Drug Administration (FDA) has issued a letter stating that the new drug application (NDA) for Entereg (alvimopan 12mg) for the management of post operative ileus (POI) is approvable. The FDA has requested 12-month safety data, including analysis of serious cardiovascular events, from study 014 (767905/014), an ongoing safety study in opioid-induced bowel dysfunction (OBD). The FDA also requested a risk management plan as part of the submission.

Prostate Cancer :: IMRT versus 3D CRT for prostate cancer

New research findings show men have fewer long-term gastrointestinal side effects with intensity-modulated radiation therapy (IMRT) than with three-dimensional conformal radiation therapy (3D CRT) for prostate cancer treatment, despite the higher doses of radiation used in the IMRT group. These and other data, including long-term genitourinary side effects, were presented today at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia.

Breast Cancer :: Breast cancer gene offers promising target for drugs

Researchers at UT Southwestern Medical Center have for the first time described how multiple copies of a gene are responsible for metastases in early-stage breast cancer and poor prognosis for patients. In a study published in this week’s issue of the Proceedings of the National Academy of Sciences, the gene, called uPAR, offers a promising target for therapeutic drugs to stop or slow the progression of the disease and could serve as a screening tool for assessing which types of drugs a patient will respond to.

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.

ADHD :: Lisdexamfetamine dimesylate in ADHD phase 3 data presented

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that their investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX), yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years who received six months of treatment in an open-label phase III study. Results also demonstrated that at 6 months, 95 percent of children taking lisdexamfetamine dimesylate (NRP104/LDX) produced a “much improved” or “very much improved” rating on the Clinical Global Impressions ? Improvement score. These results were presented last weekend at a national meeting of child and adolescent psychiatrists.

ADHD :: Many adults with psychiatric disorders may also have undiagnosed ADHD

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that many adults with a depressive disorder, Bipolar Disorder (BPD), or an anxiety disorder may also have undiagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), according to a longitudinal retrospective medical claims analysis presented today at a major medical meeting of child and adolescent psychiatrists.